Nikhil Lalwani

Great 18 minute podcast using layman terms to discuss some complex topics in the dynamic healthcare ecosystem. Take a listen and consider subscribing. I’m interested in the next episode on the topic of reimbursement vs. coverage. Thanks for sharing this Michael Navin. #marketaccess #healthcare #pbms #pharmaceuticals

12

1 Comment

Great interview about the current limitations and future potential of AI in improving healthcare!

6

Life sciences organizations face an unexpected puzzle: Productivity is up 17% since the pandemic, yet the average sales expense-to-revenue ratio has jumped 10%. What’s going on? That's a question that Raj Sharan, principal at The Alexander Group recently explored in a recent article for R&D - Research & Development World. Here's a synopsis from his article: In a post-COVID world, life sciences and analytical instrument companies have the funding, but customers are more pressed for time and budget than ever. Buyers are juggling hybrid lab schedules, rising materials costs, and strict financial constraints. This means commercial teams at analytical instruments companies must double down on two imperatives: customer-centricity: Be ready with budget-sensitive options, anticipate constraints, and arrive with solutions—not just sales pitches. Leading with science: Ensure every interaction highlights the scientific impact of your products. Showcase the data, the technical specs, and the real-world outcomes. You should be fluent in your customer’s language.

4

2 Comments

How to blow $230 million/year: - Sell a big market forecast with Standard Model thinking - Confuse said big market forecast (i.e., metrics) for a strategy - Point resources and capabilities in the wrong direction - Change said wrong direction early and as often as possible - Assume expert knowledge of the past is the way to construct a future - Ignore, misread or pretend-away the 'ground truth' from the frontline And when the mathematical gymnastics packaged in the PowerPoint don't manifest NOW in terms of the 'next $1 billion in growth' or, even better, delivering on the true center of the American Way of Healthcare (i.e., more shareholder value), throw in the towel, announce layoffs and revert to the place you're comfortable with conceptually. Says Walmart in a statement to Endpoints News: "What we learned through Walmart Health centers will help us continue to innovate and support the healthcare needs of our communities through our legacy pharmacy and vision." Possible, but not probable. By definition, the only place a "legacy" vision can lead is back to the past. If there's a "learning" here -- the kind of thing Harvard Business School can package in a PowerPoint to sell as a new corporate/executive education program -- is that making big market innovation come to life is hard work. It isn't a solo sport (Walmart can/would have fared better collaborating with a big pharmaceutical company on the roadmap). And it doesn't start with a forecast that everyone knows is bullshit, particularly the people buying and selling it. The upside of a new market is unknowable at the start, just ask the team at Amazon/Amazon Web Services (AWS), who ten years ago invented what is now a $600 billion market for 'cloud infrastructure' services. They had no idea it could be that large. But maybe the biggest learning of all is that making a Big Dent happen, particularly in healthcare, takes time, a more original vision and a completely different starting point. Quoting from the epigraph to War and Peace: "The two most powerful warriors are patience and time." via Shelby Livingston

38

17 Comments

From 2016 to 2023, Epic increased its acute care hospital market share from 26% to 39%; meanwhile, Oracle’s share held flat at about 25% until decreasing to 23% in 2023. Additionally, Epic controls 52% of the acute hospital care market by bed count, more than double that of Oracle. Thus far, Oracle and other, smaller competitors have been unable to curb Epic’s rise, as Epic was the only EHR vendor to increase its hospital-bed market share last year.

7

Thoughts on this? >> Great Learning Posts 23% Revenue Growth At $118 Million For FY24 >> Comment below! >>> lqventures.com #mhealth #healthtech #IoT #AI #industry40

1

Some great feedback from yesterday's PhyCap Fund webinar - a new approach to venture anchored by physicians. Here are some highlights of physician's unique vantage points in the world of health tech investing. 1. Real-time intelligence: Front-line docs have a critical vantage point and feel the pain of poor workflows, administrative burden, and healthcare inequity unlike any other. No one is better positioned to understand what the solutions the market demands. 2. Product Development: Companies can test and retest with physician LPs as early adopters, leading the products that are refined and more market-ready, 3. Partnerships: Scaling is hard. Many great products never scale because of the lack of a physician champion who has earned the trust of their colleagues and patients as a champion. Physicians can open the door to valuable partnerships with payers, hospitals, and groups that can accelerate adoption. PhyCap FundTracy PoolePaul Slosar, MD, MHCDSDutch Rojas Frederic Liss, M.D.Robin Noble MD, MHCDS Giovanni L. Garrett McCain Kate Evinger

34

1 Comment

As the healthcare industry continues to evolve, operations leaders face a complex set of challenges, including high administrative costs and employee attrition rates. Administrative accounts for about 25 percent of the more than $4 trillion spent on healthcare annually in the United States. Why healthcare leaders struggle to realize digital investments’ full value potential?

1

Hot off the press! CMS has recently released a video that talks about The Medicare Prescription Payment Plan and how seniors can select smoothing. This has been a concern for many pharma programs - here is the link below to share with all your colleagues to share with patients. #CMS #Medicareprescriptionpaymentplan #Medicare #Smoothing

1

5 Comments

When Omar Manejwala, M.D. shares his thoughts, I pay attention. His recent article in STAT is no exception - “The #digital-#health-as-a-#medicine business strategy contained serious flaws … Since many players in the digital health industry insisted on being treated as medicines, it stands to reason that they would also be evaluated as medicines … Put simply, products that influence a range of behaviors, conditions, and outcomes should not be narrowly evaluated on point outcomes in a single condition” #digitalhealth #digitalheathcare #innovation #healthcare https://lnkd.in/eDZa6Pv9

69

2 Comments

Life sciences organizations face an unexpected puzzle: Productivity is up 17% since the pandemic, yet the average sales expense-to-revenue ratio has jumped 10%. What’s going on? That's a question that Raj Sharan, principal at The Alexander Group recently explored in a recent article for R&D - Research & Development World. The data points are also from The Alexander Group. Here's a synopsis from the article: In a post-COVID world, life sciences and analytical instrument companies have the funding, but customers are more pressed for time and budget than ever. Buyers are juggling hybrid lab schedules, rising materials costs, and strict financial constraints. Today’s buyers want vendors who understand their scientific mission, respect their time, and come prepared with tailored, data-driven approaches. This means commercial teams at analytical instruments companies must double down on two imperatives: Customer-centricity: Be ready with budget-sensitive options, anticipate constraints, and arrive with solutions—not just sales pitches. Leading with science: Ensure every interaction highlights the scientific impact of your products. Showcase the data, the technical specs, and the real-world outcomes. You should be fluent in your customer’s language and convey clearly how you can help them. In today’s race for market share, it’s not enough to “sell”—you must solve and support.

8

Turn AI into accelerated impact. Hear from ZS leaders in the AI Pavilion at HLTH in October. Here's where to find out more: https://bit.ly/3MCPzjD #HLTH2024 #AI #HealthcareInnovation #ZSatHLTH2024

22

Thoughtful planning in the establishment of a commercial data strategy prior to brand launch can help to frame the approach to patient-centricity. Data warehouses are a lot of work to rebuild, the tips in this Beghou Consulting article help to provide four keys to inform that planning so that patients stay at the center of focus. #data #pharma #biotech #patient-centered

15

I'm excited to share the next episode of "Life Sciences DNA" podcast series about importance of Data Analytics and AI in behavioral health with Eze Abosi, the Chief Growth Officer of Holmusk. Agilisium Consulting #MentalHealth #AI #DataAnalytics #Pharma #BehavioralHealth

34

🚀 Should Pharma Companies Operate Cancer Data Platforms? Here's My Take 🚀 As the CEO of Capptoo.com, the owner of Cx-advisory.com, and a partner at Screver.com, I often consider the role of pharma in services like cancer data platforms. Reports like Roche's considering the sale of Flatiron Health raises the question: Should pharma companies be in control of these services? In my view, pharma companies are great at drug development, but when it comes to platforms like cancer data, there's a clear need for independence. Here's why: ✅ Neutrality: Independent operators build trust by ensuring unbiased data is not influenced by a single company's interests. ✅ Collaboration: An independent platform can work with multiple pharma companies, creating a richer, more comprehensive data set that benefits everyone. ✅ Trust: Patients and healthcare providers are more likely to trust platforms not directly operated by a pharma company with its products in the pipeline. 🔄 This is exactly why Oncology Compass was created with a different approach. We started with a big pharma company in partnership, but from day one, the plan was to transition to an independent operator. An independent board of oncologists reviews all articles published. The information chosen is based on medical relevance, not a company's interests. The concept of specialist peer review enhances trust and reliability, making Oncology Compass a truly independent, trustworthy source for oncology data. 🔥 Exciting news! We have a new strategic initiative for Oncology Compass coming soon...! Stay tuned for more details! At Capptoo, we help companies tackle strategic challenges. If you're navigating the healthcare data landscape, feel free to reach out to me here on LinkedIn: Michal Myszkowski #Pharma #CancerData #Oncology #Neutrality #Trust #Partnerships #Innovation For more on Roche's sale of Flatiron Health: Read the full article here: https://lnkd.in/dKEW3vX9

5

📣 Ever wondered how Medicare for All could transform healthcare in the U.S.? 🤔 Imagine a system where health insurers, PBMs, and pharmaceutical companies work together seamlessly! Here's a thought: - Implement a Medicare Advantage plan. - The plan would be administered by a company on behalf of the government. - Ensure comprehensive coverage with a capped cost. - Physicians would benefit from reduced administrative burdens. This approach could streamline processes, cut costs, and improve access to health services for everyone. 🌟 What are your thoughts on making healthcare more effective and efficient? Share your ideas in the comments! #MedicareForAll #HealthcareReform #MedicareAdvantage #HealthInsurance #PublicHealth #CostEfficiency

15

3 Comments